CN104983770A - Blood glucose reduction tablet and application thereof - Google Patents
Blood glucose reduction tablet and application thereof Download PDFInfo
- Publication number
- CN104983770A CN104983770A CN201510323098.9A CN201510323098A CN104983770A CN 104983770 A CN104983770 A CN 104983770A CN 201510323098 A CN201510323098 A CN 201510323098A CN 104983770 A CN104983770 A CN 104983770A
- Authority
- CN
- China
- Prior art keywords
- yellow bur
- food
- yellow
- medicine
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a blood glucose reduction tablet. The blood glucose reduction tablet comprises, by weight, 5 parts to 85 parts of yellow thorn fruit powder, 10 parts to 25 parts of starch and 5 parts to 30 parts of dextrin. The invention further provides a preparation method and a purpose of the tablet. Through the research, the yellow thorn fruit powder has the good blood glucose reduction function, the amount of insulin can be improved, and the blood glucose reduction effect of the tablet is equivalent to that of glibenclamide of the first-class chemical medicine of the diabetes; however, the difference is that the yellow thorn fruit powder cannot damage the liver, is good in safety and wider in applicable range and is more suitable for serving as food or health care products or medicines for preventing and treating the diabetes.
Description
Technical field
The invention belongs to field of health care products, the blood sugar lowering tablet that to be specifically related to yellow bur powder be raw material, and uses thereof
Technical background
According to statistics, the number of patients of current China diabetes has reached 9,240 ten thousand, occupies (Yang W, et al.NEngl J Med, 2010,362 (12): 1090-1101) first of the whole world.Diabetes mellitus in China medical expense is every year up to 1,734 hundred million yuan, and the direct medical expenses caused by diabetes has accounted for 13% (Alcorn T, et al.Lancet, 2012,379 (9833): 2227-2228) of Chinese medical total expenses.As can be seen here, the health of the diabetes not only serious harm people, and bring heavy financial burden for country.Thus, diabetes are prevented and treated very urgent.
Yellow thorn, Berberidaceae plant straight fringe Radix Berberidis Amurensis Berberis dasystachya Maxim., be the same with Cortex Acanthopanacis Radicis, Fructus Hippophae (black thorn) for covering, hiding, the medicinal traditional wild acinus with eating of ethnic groups such as Uygur, be referred to as " Qinghai three is stung ".In " Chinese herbal medicine handbook is commonly used in Qinghai ", Cortex berberidis dasystachyae (i.e. root bark) is documented: Cortex berberidis dasystachyae is the peel of stem of the straight fringe Radix Berberidis Amurensis of dicotyledon medicine Berberidaceae plant.Its fruit medicine function have also been made concise and to the point description, and it has treatment stomachache, dyspepsia, abdominal distention, the functions such as dysentery.
Yet there are no the real hypoglycemic report of yellow bur.
Summary of the invention
The object of the present invention is to provide a kind of blood sugar lowering tablet based on Huang thorn.Another object of the present invention is to preparation method and purposes that this tablet is provided.
Particularly, the invention provides a kind of blood sugar lowering tablet, it is that the supplementary material comprising following weight proportion is prepared from:
Yellow 5 ~ 85 parts, bur powder, starch 10 ~ 25 parts, 5 ~ 30 parts, dextrin.
Further, it also comprises correctives 1 ~ 6 weight portion, lubricant 0.1 ~ 0.6 weight portion.
Further, described correctives is citric acid, and described lubricant is magnesium stearate.
Wherein, described yellow bur powder prepares one of by the following method:
Method one: get yellow bur in fact, after drying, pulverizes, obtains yellow bur powder;
Method two: get yellow bur in fact, squeeze the juice, filter, after fruit juice drying, obtain yellow bur powder;
Method three: get yellow bur in fact, be that solvent extracts with water, after extracting solution drying, obtain yellow bur powder.
Wherein, described Huang thorn is Berberidaceae plant straight fringe Radix Berberidis Amurensis Berberis dasystachya Maxim..
Present invention also offers the preparation method of above-mentioned blood sugar lowering tablet, it comprises following operating procedure:
(3) supplementary material is got by proportioning;
(4) correctives is mixed with water, for subsequent use as binding agent; Yellow bur powder, starch and dextrin are mixed, add binding agent, granulate, then add lubricant, tabletting after mixing, obtains Tablets.
Present invention also offers the purposes of above-mentioned tablet in preparation hypoglycemic medicine, health product or food.
Wherein, described medicine, health product or food are that prevention or treatment I type, type ii diabetes are or/and the medicine of diabetic complication, health product or food.
Further, described medicine, health product or food are the medicine of the normal or impaired subjects of prevention or treatment liver function, health product or food.
The present invention studies discovery, and yellow bur can not cause liver function damage in fact, is suitable for the treatment of liver function damage diabetics equally.
Wherein, described medicine, health product or food improve the medicine of insulin level, health product or food.
Further, described medicine, health product or food improve the medicine of diabetics disorders of lipid metabolism, health product or food.
The present invention studies discovery, yellow bur powder has good blood sugar lowering, hypolipemic function, amount of insulin can be raised, its hypoglycemic activity is suitable with diabetes one line chemicals glibenclamide, but with it unlike, yellow bur powder can not cause hepar damnification, and safety is good, the scope of application is wider, is more suitable for as food, health product or the medicine for the treatment of and prevent diabetes.
Find in the present invention's research, fruit powder specific surface area is excessive, and easy moisture absorption, should not store and produce; And mobility is not good, be not easy to Production and Packaging.In view of the foregoing, yellow bur powder is prepared into tablet by the present invention, is namely convenient to the storage of product, transport and packaging, is also convenient to patient simultaneously and uses.
Detailed description of the invention
The preparation of embodiment 1 yellow bur powder tablet:
This tablet is made up of the percentage by weight of following raw material:
Yellow bur powder 50g, citric acid 3g, magnesium stearate 0.3g, starch 15g, dextrin 15g.
Concrete grammar is:
Weigh up each raw material according to proportioning, join the aqueous citric acid solution that mass concentration is 6 ~ 12%; By yellow bur powder, starch, dextrin mixing, cross 40 ~ 60 mesh sieves, homogenizing 10 ~ 15min; The mixture that homogenizing is good is added in aqueous citric acid solution, stirs after sieving, obtain coarse grain; Coarse grain is crossed 10 ~ 20 mesh sieves, dry, granulate; Add magnesium stearate, mix homogeneously, tabletting, obtain required tablet.
The preparation of yellow bur powder: get yellow bur in fact, after drying, pulverizes, obtains yellow bur powder.
The preparation of embodiment 2 yellow bur powder tablet:
This tablet is made up of the percentage by weight of following raw material:
Yellow bur powder 5g, citric acid 1g, magnesium stearate 0.1g, starch 25g, dextrin 30g.
Concrete grammar is:
Weigh up each raw material according to proportioning, join the aqueous citric acid solution that mass concentration is 6 ~ 12%; By yellow bur powder, starch, dextrin mixing, cross 40 ~ 60 mesh sieves, homogenizing 10 ~ 15min; The mixture that homogenizing is good is added in aqueous citric acid solution, stirs after sieving, obtain coarse grain; Coarse grain is crossed 10 ~ 20 mesh sieves, dry, granulate; Add magnesium stearate, mix homogeneously, tabletting, obtain required tablet.
The preparation of yellow bur powder: get yellow bur in fact, after drying, pulverizes, obtains yellow bur powder.
The preparation of embodiment 3 yellow bur powder tablet:
This tablet is made up of the percentage by weight of following raw material:
Yellow bur powder 85g, citric acid 6g, magnesium stearate 0.6g, starch 10g, dextrin 5g.
Concrete grammar is:
Weigh up each raw material according to proportioning, join the aqueous citric acid solution that mass concentration is 6 ~ 12%; By yellow bur powder, starch, dextrin mixing, cross 40 ~ 60 mesh sieves, homogenizing 10 ~ 15min; The mixture that homogenizing is good is added in aqueous citric acid solution, stirs after sieving, obtain coarse grain; Coarse grain is crossed 10 ~ 20 mesh sieves, dry, granulate; Add magnesium stearate, mix homogeneously, tabletting, obtain required tablet.
The preparation of yellow bur powder: after real for yellow bur squeezing the juice, filter, namely obtain fruit powder after fruit juice drying.
The preparation of embodiment 4 yellow bur powder tablet:
This tablet is made up of the percentage by weight of following raw material:
Yellow bur powder 30g, citric acid 2g, magnesium stearate 0.3g, starch 20g, dextrin 25g.
Concrete grammar is:
Weigh up each raw material according to proportioning, join the aqueous citric acid solution that mass concentration is 6 ~ 12%; By yellow bur powder, starch, dextrin mixing, cross 40 ~ 60 mesh sieves, homogenizing 10 ~ 15min; The mixture that homogenizing is good is added in aqueous citric acid solution, stirs after sieving, obtain coarse grain; Coarse grain is crossed 10 ~ 20 mesh sieves, dry, granulate; Add magnesium stearate, mix homogeneously, tabletting, obtain required tablet.
The preparation of yellow bur powder: get yellow bur in fact, extracting in water, namely obtains fruit powder after extracting solution drying.
The preparation of embodiment 5 yellow bur powder tablet:
This tablet is made up of the percentage by weight of following raw material:
Yellow bur powder 50g, citric acid 60g, magnesium stearate 6g, starch 150g, dextrin 50g.
Concrete grammar is:
Weigh up each raw material according to proportioning, join the aqueous citric acid solution that mass concentration is 6 ~ 12%; By yellow bur powder, starch, dextrin mixing, cross 40 ~ 60 mesh sieves, homogenizing 10 ~ 15min; The mixture that homogenizing is good is added in aqueous citric acid solution, stirs after sieving, obtain coarse grain; Coarse grain is crossed 10 ~ 20 mesh sieves, dry, granulate; Add magnesium stearate, mix homogeneously, tabletting, obtain required tablet.
The preparation of yellow bur powder: get yellow bur in fact, extracting in water, namely obtains fruit powder after extracting solution drying.
The pharmacodynamic study of the yellow bur powder of embodiment 6 the present invention
1) Experimental agents: get yellow bur in fact, after drying, pulverizes, obtains yellow bur powder.Dosage is by rat body weight, and gavage low dosage, high dose are respectively 0.4g/kg, 1.6g/kg (with yellow bur powder consumption).
2) animal: surrounding Kunming in age rat, male, regular grade, 135g, is provided by Gansu Chinese of Traditional Chinese Medicine.Be placed in laboratory in mouse cage after raising one week and carry out testing (8, every cage, temperature 22 ± 1 DEG C, humidity 42% ± 2%).Be divided into five groups: be respectively blank group of (the non-modeling of intravenous injection citrate buffer solution, ultra-pure water gavage), model group (tail vein injection STZ modeling, ultra-pure water gavage), (the tail vein injection STZ modeling of positive drug group, glibenclamide 20mg/kg gavage), (the tail vein injection STZ modeling of yellow bur powder low dose group, yellow bur powder gavage 0.4g/kg), yellow bur powder high dose group (tail vein injection STZ modeling, yellow bur powder gavage 1.6g/kg).Modeling method: fasting 16h in advance, then carries out STZ (citrate buffer solution preparation) tail vein injection 60mg/kg to it, after injection, within 72 hours, surveys its blood glucose, testing model success or not.
3) experiment reagent: 95% medical alcohol, Nanjing Ning Shi chemical reagent company limited; Normal saline, Qidu Pharmaceutical Co., Ltd., Shandong Prov.; Cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, LDL, glutamic oxaloacetic transaminase, GOT, glutamate pyruvate transaminase, lipoproteinesterase, liver esterase test kit, bio tech ltd is built up in Nanjing.
4) experimental apparatus: Bio-Rad680 type microplate reader, Bio Rad Laboratories; DS-1 type tissue homogenate instrument, Shanghai Zheng Hui Trade Co., Ltd.; TGL-16G-A type tube centrifuge, Anting Scientific Instrument Factory, Shanghai; UV-722N visible ultraviolet spectrophotometer, Shanghai Ni Ke company limited; HD type thermostat water bath, Constant Temp. Instrument Factory, Liaoyang.
5) experimentation: get healthy SD rat 40, be divided into 5 groups at random by body weight, be divided into blank group, model group, positive drug group and low, high dose group.Blank group and model group gavage every day give distilled water; Positive drug group gavage every day gives glibenclamide 1 time; Give yellow bur powder 1 time to test medicine group gavage every day, six groups give 28d all continuously; Meanwhile, its insulin and blood glucose was measured every 7 days; After last gives tested material, after anesthesia, get blood through carotid artery, acquired blood centrifuging and taking supernatant, for detecting blood lipids index and glutamic oxaloacetic transaminase, GOT, glutamate pyruvate transaminase.To its death, get rat liver tissue, wash away surperficial blood stains with normal saline, blot with filter paper, tissue homogenate instrument carries out homogenate, collects homogenate in centrifuge tube, with the centrifugal 10min of 3000rpm, Aspirate supernatant, carries out lipoproteinesterase regulating liver-QI esterase active and measures.
6) yellow bur powder reduces mensuration and the result of the blood glucose of suffering from diabetes rat body
The yellow bur powder of table 1 is on the impact (Mean ± SD) of the rat blood sugar that STZ induces
Note: with normal group comparable group
ap < 0.05; Compare with one-tenth module
bp < 0.05;
The yellow bur powder of table 2 is on the impact (Mean ± SD) of the rat insulin that STZ induces
Note: with normal group comparable group
ap < 0.05; Compare with one-tenth module
bp < 0.05;
From table 1,2, yellow bur can effectively reduce STZ blood glucose in diabetic rats in fact, raises amount of insulin, and effect is suitable with positive drug, shows the real treatment that can be used for diabetes of yellow bur.
7) yellow bur powder reduces mensuration and the result of the blood fat of suffering from diabetes rat body
The diabetes of STZ induction, can make Islet cells generation karyopycnosis, and hyaloid pathological changes.Its lipid metabolism gets muddled thereupon.The lipid metabolism of rat gets muddled simultaneously, and the enzymatic activity that relevant blood lipids index and lipid metabolism are correlated with also gets muddled.
Rat Cholesterol TC, triglyceride TG, high density lipoprotein HDL that the yellow bur powder of table 3 is induced STZ, the impact (Mean ± SD) of low density lipoprotein, LDL LDL
Note: compare with normal group
ap < 0.05 compares with one-tenth module
bp < 0.05
As shown in Table 3, low, the high dose group of the present invention yellow bur powder all has adjustment reducing effect, to high density lipoprotein by regulating effect of increasing to the cholesterol of the diabetes rat that STZ induces, triglyceride, low density lipoprotein, LDL.And in dose-effect relationship, high dose group and model group have significant difference (p < 0.05).Meanwhile, experiment shows, the effect of high dose group is suitable with the effect of glibenclamide, and glibenclamide is as the medicine of chemosynthesis, and it has certain side effect to body, and therefore, suggestion adopts natural plants and yellow bur powder can do alternative health product and uses.
HL is that the one of being synthesized by hepatic parenchymal cells has phosphorus A1 and TG hydrolytic enzyme activities, to the extracellular protein that plasma lipid transport plays an important role, main reconstruct and Chylomicron remains, the metabolism of low density lipoprotein, LDL and the antiport of cholesterol participating in HDL-C.HL vigor is abnormal has higher dependency with atherosclerosis and diabetes.LPL is the key enzyme of lipoprotein metabolism, is the key enzyme that TG in glycerol three casein is rich in hydrolysis.Its major function is the TG in hydrolysis CM and VLDL is glycerol and fatty acid.Lipoproteinesterase LPL and liver esterase HL can decompose triglyceride TG and be decomposed into glycerol and free fatty FFA, adopts cupferron to measure it and decomposes the activity that the free fatty produced just can calculate lipoproteinesterase and liver esterase respectively.
AST and ALT content is under the stimulation of some medicines, and in its body, hepatic tissue receives adipose cell and invades profit, and the relevant hepatocyte enzyme of impact is active, and in the ordinary course of things, all can have a certain impact to hepatic tissue as simvastatin and glibenclamide etc.
Table 4 yellow bur powder STZ is induced rat lipoproteinesterase LPL, liver esterase HL, glutamic oxaloacetic transaminase, GOT AST, glutamate pyruvate transaminase ALT impact (Mean ± SD)
Note: compare with normal group
ap < 0.05; Compare with one-tenth module
bp < 0.05; Compared with normal group
cp < 0.05.
Yellow bur powder can make HL and the LPL activity of experimental rat increase, and LPL removes the rate-limiting enzyme being rich in TG lipoprotein, thus has played its important function in lipoprotein circulation.The HL activity of diabetes rat can be made simultaneously to increase, thus by HL as part, promote hepatocyte picked-up cholesterol and the residual grain of Chylomicron, reduce T-CHOL and TG concentration in blood plasma, and then reach the effect regulating body disorders of lipid metabolism.
And glibenclamide positive drug group is compared for AST with ALT activity, all have reduction in various degree, positive drug group is described for liver by damaging action, yellow bur powder does not then have damaging action to liver, and there is obvious difference.
Claims (10)
1. a blood sugar lowering tablet, is characterized in that: it is that the supplementary material comprising following weight proportion is prepared from:
Yellow 5 ~ 85 parts, bur powder, starch 10 ~ 25 parts, 5 ~ 30 parts, dextrin.
2. blood sugar lowering tablet according to claim 1, is characterized in that: it also comprises correctives 1 ~ 6 weight portion, lubricant 0.1 ~ 0.6 weight portion.
3. blood sugar lowering tablet according to claim 2, is characterized in that: described correctives is citric acid, and described lubricant is magnesium stearate.
4. blood sugar lowering tablet according to claim 1, is characterized in that: described yellow bur powder prepares one of by the following method:
Method one: get yellow bur in fact, after drying, pulverizes, obtains yellow bur powder;
Method two: get yellow bur in fact, squeeze the juice, filter, after fruit juice drying, obtain yellow bur powder;
Method three: get yellow bur in fact, be that solvent extracts with water, after extracting solution drying, obtain yellow bur powder.
5. the blood sugar lowering tablet according to Claims 1 to 4 any one, is characterized in that: described Huang thorn is Berberidaceae plant straight fringe Radix Berberidis Amurensis Berberis dasystachya Maxim..
6. the preparation method of blood sugar lowering tablet described in claim 2, is characterized in that: it comprises following operating procedure:
(1) supplementary material is got by proportioning;
(2) correctives is mixed with water, for subsequent use as binding agent; Yellow bur powder, starch and dextrin are mixed, add binding agent, granulate, then add lubricant, tabletting after mixing, obtains Tablets.
7. the purposes of tablet described in Claims 1 to 5 any one in preparation hypoglycemic medicine, health product or food.
8. purposes according to claim 7, is characterized in that: described medicine, health product or food are that prevention or treatment I type, type ii diabetes are or/and the medicine of diabetic complication, health product or food.
9. the purposes according to claim 7 or 8, is characterized in that: described medicine, health product or food are the medicine of the normal or impaired subjects of prevention or treatment liver function, health product or food.
10. the purposes according to claim 7-9 any one, is characterized in that: described medicine, health product or food improve the medicine of diabetics disorders of lipid metabolism, health product or food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510323098.9A CN104983770B (en) | 2015-06-09 | 2015-06-09 | Blood sugar reducing tablet and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510323098.9A CN104983770B (en) | 2015-06-09 | 2015-06-09 | Blood sugar reducing tablet and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104983770A true CN104983770A (en) | 2015-10-21 |
| CN104983770B CN104983770B (en) | 2021-05-11 |
Family
ID=54295759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510323098.9A Active CN104983770B (en) | 2015-06-09 | 2015-06-09 | Blood sugar reducing tablet and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104983770B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1260147A (en) * | 1999-09-20 | 2000-07-19 | 青海省青藏高原生物制品有限公司 | Wolfberry fruit juice beverage |
| CN1260131A (en) * | 1999-09-20 | 2000-07-19 | 青海省青藏高原生物制品有限公司 | Reddish beautycherry jam |
-
2015
- 2015-06-09 CN CN201510323098.9A patent/CN104983770B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1260147A (en) * | 1999-09-20 | 2000-07-19 | 青海省青藏高原生物制品有限公司 | Wolfberry fruit juice beverage |
| CN1260131A (en) * | 1999-09-20 | 2000-07-19 | 青海省青藏高原生物制品有限公司 | Reddish beautycherry jam |
Non-Patent Citations (3)
| Title |
|---|
| 索有瑞等: "柴达木白刺研究现状与发展趋势", 《青海科技》 * |
| 赵晶等: "新疆小檗属果实花色苷成分的初步鉴定", 《中国食品添加剂》 * |
| 郑永霞: "花色素苷药理功效的研究进展", 《山西医药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104983770B (en) | 2021-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hernández-Corona et al. | Effect of fucoidan administration on insulin secretion and insulin resistance in overweight or obese adults | |
| Wang et al. | Ethnopharmacological use, pharmacology, toxicology, phytochemistry, and progress in Chinese crude drug processing of the lateral root of Aconitum carmichaelii Debeaux.(Fuzi): a review | |
| CN104922178A (en) | Blood glucose reducing effervescent tablet and application thereof | |
| CN102551046A (en) | Natural health composition for weight reduction and application of same | |
| CN106109580A (en) | Flos Buddlejae and extract thereof treat the application of myocardiac medicine as preparation | |
| CN103585245B (en) | Preparation method, extract and its application of common pratia herb extract | |
| CN103815397B (en) | Downgrade food compositions of blood pressure, blood fat and blood sugar and preparation method thereof | |
| CN105919111A (en) | Fruit enzyme and preparation method thereof | |
| CN107073060A (en) | Chinese cassia tree and the water extract of the Radix Astragali | |
| CN105079532A (en) | Healthcare green tea capable of reducing blood fat and loosing weight and preparation method of healthcare green tea | |
| CN108926595A (en) | A kind of health care product with protection liver and hypolipemic function | |
| CN104983770A (en) | Blood glucose reduction tablet and application thereof | |
| CN103705768B (en) | The compositions of prevention alcoholic liver disease and application thereof | |
| CN104945525B (en) | Yellow bur reality polysaccharide and its preparation method and application | |
| CN104922180A (en) | Blood glucose reducing capsule and application thereof | |
| CN109381505A (en) | A kind of Chinese medical extract and combinations thereof and for antifatigue purposes | |
| Zhou et al. | Data on the optimization of the formula of Xiaokeyinshui extract combination treating diabetes mellitus using uniform experimental design in mice | |
| CN104906163B (en) | Yellow bur reality and its hypoglycemic purposes of extract | |
| Wang et al. | Liuwei Dihuang exhibits antidiabetic effects through inhibiting α-amylase and α-glucosidase | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof | |
| CN104983771B (en) | Yellow bur improves the purposes of disorders of lipid metabolism in fact | |
| CN110507759A (en) | A kind of three yellow Chinese herbal preparation of particles and preparation method thereof with control hyperglycemia | |
| CN111480846A (en) | Health-care product for assisting in reducing blood fat and improving immunity | |
| CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament | |
| CN104971080B (en) | Yellow bur reality polysaccharide improves the purposes of disorders of lipid metabolism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |